WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006085033) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/085033    International Application No.:    PCT/FR2006/050117
Publication Date: 17.08.2006 International Filing Date: 09.02.2006
IPC:
G01N 33/574 (2006.01), A61K 31/00 (2006.01), A61K 38/00 (2006.01)
Applicants: CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES [FR/FR]; 60, rue du Capitaine FERBER, F-75020 Paris (FR) (For All Designated States Except US).
CUSSENOT, Olivier [FR/FR]; (FR) (For US Only).
VALLANCIEN, Guy [FR/FR]; (FR) (For US Only).
FROMONT, Gaëlle [FR/FR]; (FR) (For US Only)
Inventors: CUSSENOT, Olivier; (FR).
VALLANCIEN, Guy; (FR).
FROMONT, Gaëlle; (FR)
Agent: MICHELET, Alain; Cabinet HARLE et PHELIP, 7, rue de Madrid, F-75008 Paris (FR)
Priority Data:
0550387 09.02.2005 FR
Title (EN) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
(FR) COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT DU CANCER DE LA PROSTATE
Abstract: front page image
(EN)The invention relates to a pharmaceutical composition, comprising a compound with a negative regulatory effect on the expression of protein BCAR-1, together with at least one acceptable pharmaceutical vehicle. Said pharmaceutical composition is particularly of use for the treatment of prostate cancers even when the above have become resistant to treatment by anti-androgenic compounds. The invention further relates to methods for detection and assessment of the malignancy of a prostate cancer in vitro.
(FR)L'invention concerne une composition pharmaceutique comprenant un composé qui régule négativement l'expression de la protéine BCAR-1, en association avec au moins un excipient pharmaceutiquement acceptable. Une telle composition pharmaceutique permet notamment de traiter des cancers de la prostate même lorsque ceux-ci sont devenus résistants aux traitements par des composés antiandrogéniques. L'invention concerne également des procédés de détection, et d'évaluation in vitro de l'agressivité d'un cancer de la prostate.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: French (FR)
Filing Language: French (FR)